CN106420826A - Application of oriental latrine fly larvina product in preparing drugs, health care products or foods for treating lymphoma - Google Patents
Application of oriental latrine fly larvina product in preparing drugs, health care products or foods for treating lymphoma Download PDFInfo
- Publication number
- CN106420826A CN106420826A CN201610808550.5A CN201610808550A CN106420826A CN 106420826 A CN106420826 A CN 106420826A CN 201610808550 A CN201610808550 A CN 201610808550A CN 106420826 A CN106420826 A CN 106420826A
- Authority
- CN
- China
- Prior art keywords
- larvina
- maggot
- product
- latrine fly
- oriental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims abstract description 8
- 241000202815 Chrysomya megacephala Species 0.000 title abstract description 13
- 206010025323 Lymphomas Diseases 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 229920001661 Chitosan Polymers 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241000257161 Calliphoridae Species 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000010981 turquoise Substances 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000134068 Mesostigma Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000021170 buffet Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of tumor therapy, in particular to an application of an oriental latrine fly larvina product in preparing drugs, health care products or foods for treating lymphoma. The oriental latrine fly larvina product provided by the invention, as a natural product, contains whole oriental latrine fly larvina as active ingredients. Modern medical researches prove that the oriental latrine fly larvina contains protein, fat, chitosan, antibacterial peptides and 18 amino acids. According to the invention, dry powder of the oriental latrine fly larvina contains all active ingredients of the whole oriental latrine fly larvina, and extracts of the oriental latrine fly larvina mainly include fatty acid and/or protein, polypeptide, amino acids and the like. Based upon studies, the oriental latrine fly larvina product can effectively inhibit the growth of the lymphoma, and the oriental latrine fly larvina product, different from chemotherapeutic drugs which are commonly used in the clinical field, is free from drug tolerance as well as toxic and side effects.
Description
Technical field
The present invention relates to a kind of therapeutic field of tumor, more particularly, to maggot product are used for preparation treats lymphadenomatous medicine
Application in product, health products or food.
Background technology
Maggot is Calliphoridae（Calliphoridae）Insect chrysomyia megacephala（ChrysomyiamegacephalaFab.）
Or other nearly edge insects larva body is dried, just on the books, for treating infantile malnutrition, pustule sore in medical book in ancient times.
Record maggot at present and there is following pharmacological action：1. antiasthmatic effect, the total amino acid contained by maggot is to relieving asthma
Active ingredient；2. the effect that pair intestines smooth, maggot ethanol extract and maggot total amino acid CE are to histamine institute
The ileum smooth muscle spasm of cause isolated rabbit and cavy all has significantly strives convulsion effect；3. toxicity, the toxicity very little of maggot.
Chinese invention patent application（Application number CN200510060277.4 applying date 2005.08.04）One kind has anti-
The cultural method of knubble biological activity fly maggot.Through The National Center for Drug Screening, in the past few years repeated detection has to liver the fly maggot of cultivation
Cancer, breast cancer, oophoroma, cervical carcinoma, lung cancer, cancer of the stomach, etc. growth of tumour cell have very strong inhibiting rate, its anti-tumor biological live
Property is all 75%～97%.
Chinese invention patent application（Application number CN200710067951.0 applying date 2007.04.10）Disclose a class
Antitumoral compounds, this component extracting and developing from the fly maggot that allogenic material induces obtains, and has the suppression white blood of the former myelocyte of people
Sick HL-60 and the effect of human pulmonary epithelial cells propagation growth.
Chinese invention patent application（Application number CN201310223817.0 applying date 2013.06.06）Disclose one kind
Novel antitumor application of maggot, is showed by the effect that maggot suppresses mouse tumor weight, maggot can suppress tumour thin
The growth of born of the same parents, has lethal effect to tumour cell, can apply, specifically disclose in preparing antineoplastic or health products
The growth inhibition of S180 sarcoma.
Lymthoma is initiated by the malignant tumour of lymphohematological, is mainly shown as Silent Neuritis enlargement of lymph nodes, liver spleen
Enlargement, each histoorgan of whole body all can be involved, the heat that occurs together, night sweat, become thin, the constitutional symptom such as itch.Malignant lymphoma is that have
A quite heterogeneous big class tumour although being apt to occur in lymph node, but due to lymphoid characteristic distributions so that lymthoma
Belong to systemic disease, almost can invade any tissue of whole body and organ.
Content of the invention
First purpose of the present invention is to provide maggot product to be used for preparation to treat the application in lymphadenomatous medicine.
Second object of the present invention is to provide maggot product to be used for preparation to suppress the application in lymphadenomatous health products.
Second object of the present invention is to provide maggot product to be used for preparation to suppress the application in lymphadenomatous food.
Preferably, above-mentioned maggot product be maggot dry powder and or maggot extract and maggot dry powder
With or maggot extract preparation preparation.
As further preferably, described preparation is capsule, tablet, pill, powder, compound granule, health liquor, albumen
Powder, oral liquid or freeze-dried powder.
Preferably, above-mentioned maggot extract includes the water extract of the full worm of maggot or maggot dry powder and organic
One or more of solvent extractable matter.
As further preferably, the organic solvent in described extractive with organic solvent is included in ethanol, petroleum ether or hexane
One or more.
The maggot product of the present invention is a kind of natural product, and maggot product active ingredient is the full worm of maggot, existing
Prove for medical research：Contain protein, fat, chitosan in maggot, contain antibacterial peptide and 18 kinds of amino acid.The present invention
Maggot dry powder in include all active ingredients of the full worm of maggot, maggot extract mainly with aliphatic acid and/or
Protein, polypeptide, amino acid etc..It has been investigated that, maggot product effectively can suppress lymphoma growth, and maggot product
There is no the resistance of chemotherapeutic clinically commonly used and its toxic and side effect.
Specific embodiment
Embodiment 1
1st, Hylemyia Platura Meigen selects
Zoology is identified：Calliphoridae Calliphoridae insect chrysomyia megacephala Chrysomyia megacephala (Fab.).
8 ~ 11 millimeters of adult flies body length, turquoise, head width, top black；Compound eye is big, peony, frontalia maroon, face and cheek
Orange-yellow, feeler and palpuli brown.Chest, belly turquoise, with purple gloss.1st uromere and the 2nd, 3 uromere trailing edge are black
Color.The forehead of female fly and middle bar slightly protrude laterally in center.The facet of big shape, lower section are arranged at male fly compound eye top 2/3
1/3 facet for little shape, the two interface is clear.Prothoracic spiracles black, mesostigma is light brown；There is valve.Proxacalypteron band palm fibre
Color, above has little Mao.Yellow-white during larval maturation, front end is tapering, and rear end is truncated.Body segment 14, head 1 saves, and chest 3 saves, belly
10 sections, but generally only see 8 sections.The ring that body surface is formed by clavula.Valve is slightly higher than surface afterwards, more flat in top, spiracular annulus is not
Completely；The transverse diameter of valve after valve spacing is not more than afterwards；The vertical shape of 1st ostium；Front valve has 10 13 finger-like and dashes forward.
2nd, Hylemyia Platura Meigen collection
(1) making of Hylemyia Platura Meigen case：Wooden, glass, ceramic making can be selected, circular or rectangle, top stays one directly
The mouth that 25 centimetres of footpath, and make the netted lid that a use is breathed freely, in case Hylemyia Platura Meigen escapes.
(2) Hylemyia Platura Meigen feed configuration：Milk powder+brown sugar, 1:1 mixing, the water plus 15% is in harmonious proportion, is positioned in Hylemyia Platura Meigen case.
(3) open the netted lid of Hylemyia Platura Meigen case, be placed in 28--38 degree Celsius, humidity is less than in 65% environment.
Allow the chrysomyia megacephala in the external world to enter in cartonning to look for food, undesirable fly kind is carried out with sorting and abandons, and cover net
Shape lid is looked for food, lays eggs so as to be stranded in Hylemyia Platura Meigen case.
3rd, cultivation hardware and breeding feed
(1) fly house is built：By cultivation scale, masonry can be selected, glass, plastics, steel frame construction material, 2 meters about from the ground
Body of wall on interval 1.5--2 rice setting vent window, for preventing other flies or insect from entering, be preferably provided with screen window with extraneous every
From above box for breeding, a metric system becomes mobilizable ventilation shaft, is easy to gas sampling, prevents emission of bad smell pollution environment, gives up
Gas unification is discharged after being processed by ozone deodorizer.For preventing fly kind from entering gas sampling pipeline, preferably arrange in each air inlet
Screen window separates.
(2) box for breeding makes：Wooden, ceramic, cement material can be selected, make rectangular box, bottom arranges sealing
Sealing device, stays the circular hole of 30--40 centimetre of a diameter above casing, you can.It is provided with sewage collecting below each box for breeding to lead to
Road, unified entrance after cesspool is processed is discharged.
(3) it is incubated：For meeting the standardisation requirements of cultured product, can set up heat, cooling installation.In sweltering heat, season can
In fly house top surface, anti-sunshading facility is set.
(4) breeding feed：Haslet, fresh-water fishes, bullfrog, milk powder, honey.
4th, breeding technique step
(1) fly kind：The fly kind of collection is transplanted to and is carried the previous day and be placed with the Hylemyia Platura Meigen case of fresh-water fishes, cultivates 2 days, treats it in case
Spawning.
(2) collect fly blow：Treat that Hylemyia Platura Meigen lays eggs in fly kind case, you can fly blow is collected, transfers to the fly house added with feed
Carry out in box for breeding hatching, cultivate, the ratio of feed and fly blow is every 5 grams of fly blows, adds 15 kilograms of feed.
(3) hatching cultivation：After fly blow hatching, you can obtain required feed in box for breeding, generally require 72 hours,
Polypide grows to length 1--1.2 centimetre, during diameter 2.5--3 millimeter.
(4) active catalytic：The super oxygen with 200 milliliters of prewired 5% sucrose (w/w) aqueous solution and 1% is added in box for breeding
Compound mutase（LA-SOD）500 milliliters of (activities of the enzyme systems is more than 3,000,000 units/gram), after 2 hours, take out live body maggot,
Repeatedly rinsed well with clear water, at once put into quick-frozen in less than 38 degrees Celsius of refrigerator-freezer.
(5) cleaning-drying：Low-temperature quick-freezing two days later, takes out, and melts, more carefully cleans, drain away the water in clear water, uses
Vacuum dehydrating at lower temperature equipment is dried to moisture and is less than 10%.
Test example 1
First, experiment purpose
Evaluate the extracorporeal anti-tumor function to people Burkitt ' s lymphoma cell Raji for the maggot.
2nd, major experimental instrument and material
1. key instrument
Wavelengthtunable declines orifice plate ELIASA.
2. main agents
Freeze-dried powder after water extraction for the maggot full worm powder, our company confesses；1640 fluid nutrient mediums, purchased from the triumphant base in Nanjing
Biotech firm；Hyclone, MTT.
3rd, experimental technique and step
Experimental technique:
MTT principle:MTT, a kind of dyestuff of yellow color.In living cells mitochondria, succinate dehydrogenase metabolism can reduce MTT, with
When in the presence of cromoci, generate blue（Or bluish violet）Water-fast first（Formazan）, the number of first can
To be measured at 490nm with ELIASA.Under normal conditions, first growing amount is directly proportional to viable count, therefore can root
Deduce the number of living cells according to optical density OD value.Due to not containing succinate dehydrogenase in dead cell, therefore addition MTT will not
There is reaction.
Experimental procedure：
1:Collect logarithmic phase cell, adjust concentration of cell suspension, every hole adds 150ul, bed board makes cell to be measured adjust density 1*
105/ hole,（Edge hole is filled with aseptic PBS）.
2: 5%CO2, 37 DEG C of incubations, it is paved with bottom hole to cell monolayer（96 hole flat undersides）, add the medicine of 3 concentration gradients
（0.25mg/ml、0.5mg/ml、1mg/ml）, every hole 50ul, if 3 multiple holes. and zero hole simultaneously（Culture medium, MTT, dimethyl are sub-
Sulfone）, control wells（Cell, the medicine dissolving medium of same concentrations, nutrient solution, MTT, dimethyl sulfoxide (DMSO)）;5%CO2,37 DEG C of incubations
48 hours, observe under inverted microscope.
3:Every hole adds 20ulMTT solution（5mg/ml）, continue culture 4h;Terminate culture, carefully suck the every hole of in the hole nutrient solution
Add 200ul dimethyl sulfoxide (DMSO), put low-speed oscillation 10min on shaking table, so that crystal is fully dissolved.Enzyme-linked immunosorbent assay instrument
The light absorption value in each hole is measured at OD490nm.
4：Calculate the inhibiting rate to cancer cell growth for the test compound by following equation.
Inhibiting rate=（1- control group OD value/administration group OD value）×100%
4th, experimental result：
Table：The inhibiting rate to Raji cell growth for the sample
| Numbering | 0.25mg/ml | 0.5mg/ml | 1mg/ml |
| A12 | 56.91% | 62.23% | 22.66% |
This MTT experiment testing result shows：Sample A12 has the activity of suppression human lymphoma cell, other samples in low concentration
Product but dosage increase after inactive.
Test example 2
Turn round and look at * *, male, 56 years old, address：Jiangsu, in September, 2011 is made a definite diagnosis in Lianyun Harbour * * hospital, is diagnosed as lymphoblastoma, doctor
Institute's therapeutic effect treatment curative effect is not good enough, subsequently abandons continual cure.
Medical record brief introduction：
After being introduced, start to take antitumor maggot in December, 2011, take medicine in April, 2012, existing patient recovers base
This life, no significant discomfort, and start to manage buffet, the overall state of mind is good, stable disease.
Test example 3
Lee * *, male 46 years old address：Anji County, Zhejiang Province county
It is diagnosed as Fei Huojinqi lymthoma in November, 2013（Diffusivity large B cell）, many places transfer, pleural effusion, pericardium is few
Amount hydrops, IV-b phase.Combine CHOP chemotherapy in December, 2013 in Shanghai Huashan Hospital's row Mabthera, after first time chemotherapy, in vain
TCS is less than 1000, gives G-CSF 100ug, continuous 7 days, leaves hospital.Chemotherapy starts to take always antineoplastic after one week
With maggot, three times a day, 1.2 grams every time., second-～-the five chemotherapy hereafter, leucocyte is all in normal range (NR).And
Obvious alopecia and bone marrow suppression do not occur.After end of chemotherapy, PET-CT check, after peritonaeum, groin remain 0.8 centimetre of size
Enlarged lymph node.And continue to take antitumor maggot.
Patient is respectively at 2104.01 201406. 201412. 201505 checks, all METs, pleural effusion.Pericardium
Hydrops all disappears, and starts normally to go to work so far in August, 2014.
This patient is continuous to be used 1 year.
Claims (7)
1. maggot product is used for the application in the preparation lymphadenomatous medicine for the treatment of.
2. maggot product is used for preparation and suppresses the application in lymphadenomatous health products.
3. maggot product is used for preparation and suppresses the application in lymphadenomatous food.
4. the application according to claim 1 ~ 3 any one claim is it is characterised in that maggot product is maggot
Dry powder and or maggot extract and maggot dry powder and or the preparation of maggot extract preparation.
5. application according to claim 4 is it is characterised in that preparation is capsule, tablet, pill, powder, compound granular
Agent, health liquor, albumen powder, oral liquid or freeze-dried powder.
6. application according to claim 4 is it is characterised in that maggot extract includes the full worm of maggot or maggot does
One or more of the water extract of powder and extractive with organic solvent.
7. application according to claim 6 is it is characterised in that the organic solvent in extractive with organic solvent includes ethanol, stone
One or more of oily ether or hexane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/100684 WO2018045959A1 (en) | 2016-09-08 | 2017-09-06 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610111367 | 2016-02-26 | ||
| CN201610111367X | 2016-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420826A true CN106420826A (en) | 2017-02-22 |
Family
ID=57709748
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610808840.XA Pending CN106420828A (en) | 2016-02-26 | 2016-09-08 | Application of maggot product in preparation of medicines or health-care products or food for treating pancreatic cancer |
| CN201610808600.XA Pending CN106265752A (en) | 2016-02-26 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of carcinoma of prostate, health product or food |
| CN201610808701.7A Pending CN106214705A (en) | 2016-02-26 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of lung squamous cancer, health product or food |
| CN201610809035.9A Pending CN106344615A (en) | 2016-02-26 | 2016-09-08 | Application of Larva Chrysomyiae products to preparation of drugs, health care products or foods for treating non-small cell lung cancers |
| CN201610808550.5A Pending CN106420826A (en) | 2016-02-26 | 2016-09-08 | Application of oriental latrine fly larvina product in preparing drugs, health care products or foods for treating lymphoma |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610808840.XA Pending CN106420828A (en) | 2016-02-26 | 2016-09-08 | Application of maggot product in preparation of medicines or health-care products or food for treating pancreatic cancer |
| CN201610808600.XA Pending CN106265752A (en) | 2016-02-26 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of carcinoma of prostate, health product or food |
| CN201610808701.7A Pending CN106214705A (en) | 2016-02-26 | 2016-09-08 | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of lung squamous cancer, health product or food |
| CN201610809035.9A Pending CN106344615A (en) | 2016-02-26 | 2016-09-08 | Application of Larva Chrysomyiae products to preparation of drugs, health care products or foods for treating non-small cell lung cancers |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN106420828A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (en) * | 2016-09-08 | 2018-03-15 | 黄玉水 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
| CN111617109A (en) * | 2020-06-11 | 2020-09-04 | 杭州益科堂生物科技有限公司 | Application of maggot medicament, maggot medicament and preparation method thereof |
| WO2021208280A1 (en) * | 2020-04-17 | 2021-10-21 | 杭州益科堂生物科技有限公司 | Application of dried fly larva in preparation of drugs for preventing and treating breast hyperplasia |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110327374B (en) * | 2019-07-31 | 2020-07-28 | 浙江佰科堂生物科技股份有限公司 | A pharmaceutical composition prepared from maggot for preventing and/or treating convulsion |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736186A (en) * | 2005-08-04 | 2006-02-22 | 周志钦 | Method for breeding fly maggot with anti-tumor biological characteristic |
| CN101991608A (en) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | Fly maggot extractive as well as preparation method and application thereof |
| CN103271947A (en) * | 2013-06-06 | 2013-09-04 | 四川科伦新光生物科技开发有限公司 | Novel antitumor application of maggot |
-
2016
- 2016-09-08 CN CN201610808840.XA patent/CN106420828A/en active Pending
- 2016-09-08 CN CN201610808600.XA patent/CN106265752A/en active Pending
- 2016-09-08 CN CN201610808701.7A patent/CN106214705A/en active Pending
- 2016-09-08 CN CN201610809035.9A patent/CN106344615A/en active Pending
- 2016-09-08 CN CN201610808550.5A patent/CN106420826A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736186A (en) * | 2005-08-04 | 2006-02-22 | 周志钦 | Method for breeding fly maggot with anti-tumor biological characteristic |
| CN101991608A (en) * | 2010-11-19 | 2011-03-30 | 浙江省医学科学院 | Fly maggot extractive as well as preparation method and application thereof |
| CN103271947A (en) * | 2013-06-06 | 2013-09-04 | 四川科伦新光生物科技开发有限公司 | Novel antitumor application of maggot |
Non-Patent Citations (2)
| Title |
|---|
| 云贵: "水仙子昆虫蛋白研究概况", 《上海医药》 * |
| 李黔军、黄雪飞: "蝇蛆蛋白的研究进展", 《养殖技术顾问》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018045959A1 (en) * | 2016-09-08 | 2018-03-15 | 黄玉水 | Applications of oriental latrine fly larvina product in producing cancer-treating drug, health product or food product |
| WO2021208280A1 (en) * | 2020-04-17 | 2021-10-21 | 杭州益科堂生物科技有限公司 | Application of dried fly larva in preparation of drugs for preventing and treating breast hyperplasia |
| CN111617109A (en) * | 2020-06-11 | 2020-09-04 | 杭州益科堂生物科技有限公司 | Application of maggot medicament, maggot medicament and preparation method thereof |
| CN111617109B (en) * | 2020-06-11 | 2023-12-22 | 杭州益科堂生物科技有限公司 | Application of five-cereal insect medicament, five-cereal insect medicament and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106265752A (en) | 2017-01-04 |
| CN106420828A (en) | 2017-02-22 |
| CN106214705A (en) | 2016-12-14 |
| CN106344615A (en) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106420826A (en) | Application of oriental latrine fly larvina product in preparing drugs, health care products or foods for treating lymphoma | |
| CN111297969A (en) | Application of Chaihingzhi preparation in preparing anti-coronavirus medicine and its preparation method | |
| CN106420827A (en) | Application of Larva ChrysomyiamegacephalaFab. product in preparing dugs, health care products or foods for treating colon cancer | |
| CN102242079A (en) | Medium for producing Paecilomyces cicadae spore, culture method thereof, culture product thereof and application thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN110896784A (en) | Substitute cultivation medium, substitute cultivation method and application of inonotus obliquus | |
| CN102212581A (en) | Preparation method and application of cordyceps polysaccharide germanium | |
| KR20150014033A (en) | Food composition for liver activity contaning Water extract of Cordyceps militaris and its manufacturing method | |
| CN105749154B (en) | A kind of probiotics fermention Traditional Chinese medicine compound composition that treating liver cancer and its preparation and detection method | |
| CN101245334A (en) | Technique for suspension cultivation of algam dendrobium nobile embryoid of medicinal effective composition of native plant strain | |
| CN104856980A (en) | Medical uses of tetrahydrocurcumin | |
| CN104922268B (en) | A kind of method that active material is extracted from natural plants | |
| CN107982356B (en) | Oral medicine for treating respiratory tract infection | |
| CN104906162A (en) | Preparing method and application of rhizoma atractylodis volatile oil | |
| CN106420829A (en) | Application of maggot product to preparation of medicine, health care product or food for treating gliocytoma | |
| Molefe | Anthelmintic, anticancer and phytochemical screening of Cotyledon orbiculata; Hermannia depressa; Nicotiana glauca and potassium permanganate | |
| CN105769895A (en) | intervention effect of cyanidin-3-O-glucoside on reproductive toxicities of acrylamide and glycidamide | |
| CN106265753A (en) | Chrysomyiame gacephala (Fab.) goods are for preparing the application in the treatment medicine of Leydig's cell tumor, health product or food | |
| CN107661359A (en) | A kind of paecilomycerol pupa base cordyceps sinensis composition of strengthen immunity anti-aging and its application | |
| CN104873493B (en) | Application of the 2 hydroxyl eupatolides in antineoplastic is prepared | |
| CN112957388B (en) | Application of brassica napus-isatis tinctoria E monomer addition system in inhibiting influenza virus | |
| CN101066410B (en) | Chinese medicine preparation for treating women's chronic pelvic inflammation and its preparation process | |
| CN105055504A (en) | Feed additive compound essential oil for preventing diarrhea of pigeons as well as preparation method and application of essential oil | |
| CN106860781A (en) | A kind of application of Rhizopus oryzae solid state fermentation extract, preparation method and its anticancer function | |
| CN106039164A (en) | Traditional Chinese medicine powder for treating coccidiosis in chicken and preparation method of traditional Chinese medicine powder for treating coccidiosis in chicken |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |